Anthropic Enters AI Drug Discovery Fray with 'Claude Science,' Challenging Google and OpenAI

Anthropic has officially thrown its hat into the AI-driven drug discovery ring with the launch of 'Claude Science,' an integrated platform for life sciences research, challenging early movers Google and OpenAI. The move comes as Anthropic eyes an initial public offering (IPO) as early as this fall, with the foray into the pharmaceutical market representing a strategic push to significantly expand its business-to-business (B2B) revenue.

Anthropic first showcased Claude Science on June 30 (local time) at 'The Briefing: AI for Science' event in San Francisco. The product is not a new AI model but rather a workbench designed to allow researchers to evaluate scientific literature and execute analyses, built on top of Anthropic's existing Claude models.

Eric Cauderer-Abrams, Anthropic's Head of Life Sciences, stated during the presentation that the company would prioritize "neglected diseases" that large pharmaceutical companies have overlooked due to profitability concerns. Claude Science automates biological and chemical experimental processes such as protein structure prediction, integrating over 60 pre-configured scientific databases spanning genomics, proteomics, single-cell analysis, and cheminformatics into a single interconnected system.

The platform's core is a central AI assistant. This assistant orchestrates research tasks while also capable of spawning sub-agents for specialized subtasks. Researchers can also delegate work to custom agents built around their specific interests. A separate reviewer agent checks citations and calculations, flagging errors before results are incorporated into manuscripts. However, Anthropic made clear that this review function relies on the same underlying model and is not an independent verification source.

Every output generated on the platform comes with an 'auditable history.' This includes every step leading to the result, such as the code that generated a figure, the environment in which the code ran, an accessible explanation of the methodology, and the complete message log. Researchers can fork a session at any time to compare two analytical approaches while preserving the original analysis flow.

Claude Science is currently available in beta to all Claude Pro, Max, Team, and Enterprise subscribers. Anthropic disclosed Novo Nordisk and the Allen Institute as early adopter case studies. Jerome Lecoq, a neuroscientist at the Allen Institute, built a multi-agent flow within the platform that reads thousands of papers and extracts key claims and quantitative findings. TechCrunch reported that Stephen Francis's group at the UCSF Brain Tumor Center completed a germline analysis of glioma in a dramatically shortened timeframe compared to traditional methods.

Anthropic also announced a program offering credits worth up to $30,000 (~41 million won) per project for up to 50 research projects. Applications close on July 15, 2026, with selections announced on July 31.

The AI drug discovery market has already emerged as the next major battleground for global technology companies. Google DeepMind operates the 'Gemini for Science' platform, which combines foundational science models like AlphaFold and AlphaGenome with over 30 life sciences databases. DeepMind's subsidiary, Isomorphic Labs, is on the verge of entering clinical trials with drug candidates designed by its own AI.

OpenAI launched 'GPT-Rosalind,' a model specialized in biological reasoning, in April 2026. The model is currently offered on a limited basis only to qualified corporate customers who have passed a safety review within the United States. In contrast, Anthropic is differentiating itself by emphasizing an open subscription access model and easy integration, making the tool available to all existing Claude subscribers rather than creating a new specialized model.

The market reacted sharply immediately following Anthropic's announcement. Shares of Schrödinger (SDGR), which uses physics-based simulations to find drug candidates, briefly plunged 8.3%. Recursion Pharmaceuticals (RXRX), which combines AI and automated robotic labs to analyze biological data, also saw increased intraday losses before partially recovering, highlighting heightened volatility in related stocks.

Anthropic has already confidentially filed paperwork with the U.S. Securities and Exchange Commission (SEC) for an IPO. Yahoo Finance analyzed that the expansion into vertical products like Claude Science aligns with Anthropic's pattern of building additional revenue streams ahead of its public listing.